INTRODUCTION {#S2}
============

Multiple post-translational modifications on the epsilon-amino group of lysine regulate protein functions. Recent studies have added lysine succinylation, which has been observed in many species ([@R3]; [@R16]; [@R19]; [@R21]; [@R22]), as an additional lysine modification. Sirtuin (SIRT) 5 can remove succinyl modifications from lysine ([@R5]). Indeed, recent studies showed that increased accumulation of succinyl-coenzyme A (CoA) caused increased lysine succinylation, likely because of non-enzymatic lysine succinylation ([@R10]; [@R20]; [@R21]). However, given that (1) lysine acetylation is catalyzed by acetyltransferases even though acetyl-CoA can non-enzymatically acetylate lysines ([@R2]) and (2) regulatory post-translational modifications are typically catalyzed by enzymes, it is likely that there is a lysine succinyltransferase (LSTase) that catalyzes the forward reaction of lysine succinylation using succinyl-CoA as a substrate.

Therefore, succinyl-CoA is considered to be a putative substrate for an LSTase. It was also shown, more than 30 years ago, that short-chain dicarboxylic-acyl-CoAs, including succinyl-CoA, bind to carnitine palmitoyltransferase 1A (CPT1A) and inhibit its carnitine palmitoyltransferase (CPTase) activity ([@R12]; [@R13]). CPT1A catalyzes the formation of long-chain acylcarnitines from long-chain acyl-CoAs and carnitine, the rate-limiting step of mitochondrial fatty acid oxidation (FAO) that metabolizes fatty acids into acetyl-CoA to produce ATP in mitochondria. Although the inhibitory effect of succinyl-CoA on CPTase activity is well accepted in the field, how succinyl-CoA binds to CPT1A remains unclear because of the lack of the crystal structure of the CPT1A protein. In this study, we show that CPT1A is able to use succinyl-CoA as a substrate to function as an LSTase *in vitro* and *in vivo*. Our SILAC-based quantitative succinylation proteomics analysis identified 171 lysine sites on 101 proteins (out of 550 lysine sites on 247 proteins total) that were succinylated in a CPT1A expression-dependent manner in cells. Importantly, the CPTase activity and the LSTase activity of CPT1A can be separated by mutation of CPT1A Gly710 (G710E). Using this CPT1A G710E mutant, we show that the LSTase activity of CPT1A inhibited enolase 1 enzymatic activity and promoted cell proliferation under glutamine depletion. Thus, we propose that CPT1A regulates cellular metabolism by succinylating substrate proteins independent of its canonical CPTase activity.

RESULTS AND DISCUSSION {#S3}
======================

Identification of CPT1A as a Potential LSTase {#S4}
---------------------------------------------

Because succinyl-CoA is a short-chain acyl-CoA, we hypothesized that acyltransferases with CoA binding domains may have LSTase activity. To identify potential candidates, we first searched the Swiss-Prot database using "acyltransferase" and "CoA binding" as keywords and obtained 33 candidate proteins ([Figure S1A](#SD6){ref-type="supplementary-material"}). We next excluded acyltransferases expressed in yeast, because yeasts do not express desuccinylases (e.g., SIRT5) that would be expected to reverse succinylation catalyzed by an LSTase. After these screening steps, we obtained nine candidates, including all CPT family members ([Figure S1A](#SD6){ref-type="supplementary-material"}). Among the CPT family members, CPT1A is the most expressed isoform in the liver, where lysine succinylation occurs at highest levels compared with other tissues ([@R16]; [@R19]). Interestingly, short-chain dicarboxylic-acyl-CoAs, including succinyl-CoA, are known to inhibit the CPTase activity ([@R12]; [@R13]). A structural modeling study of CPT1A proposed two potential CoA binding pockets within the active site ([@R11]). Also, lysine succinylation and carnitine acylation are quite different in terms of chemical reactivity and steric occlusion because lysine succinylation is linked to the epsilon-amino group of lysine, whereas carnitine acylation occurs on a secondary hydroxyl group. Thus, we hypothesize that succinyl-CoA may bind to a locus different from the palmitoyl-CoA-binding locus within the CPT1A active site, which triggers CPT1A to have an additional enzymatic activity: the ability to succinylate lysine residues. To examine this hypothesis, we generated human 293T cell lines stably expressing wild-type (WT) human CPT1A and vector control and measured the total lysine succinylation levels in lysates by western blotting (WB) with a pan anti-succinylated lysine antibody. Expression of CPT1A WT increased the total lysine succinylation levels in 293T cell lysates compared with expression of vector control ([Figure 1A](#F1){ref-type="fig"}, left). We next measured intracellular succinyl-CoA levels in 293T cell lines expressing CPT1A WT and vector control by an isotope-ratio-based approach with gas chromatography (GC)/mass spectrometry (MS) as we have performed previously ([@R6]). The detailed calculations of intracellular succinyl-CoA levels in the cells are described in [Figure S1B](#SD6){ref-type="supplementary-material"}. Using this isotope-ratio based approach, we found no significant increase in succinyl-CoA levels by expression of CPT1A WT compared with expression of vector control in 293T cells, indicating that the increase in lysine succinylation by CPT1A WT is not due to higher intracellular succinyl-CoA levels ([Figure 1A](#F1){ref-type="fig"}, right). We also measured NAD^+^ concentration in vector and CPT1A WT-expressed 293T cells and found no significant change in NAD^+^ concentration by CPT1A expression ([Figure S1C](#SD6){ref-type="supplementary-material"}). These results suggest that CPT1A may function as an LSTase in cells. In addition, we sought to investigate whether CPT1A is the specific enzyme that has the observed LSTase activity. We examined lysine succinylation levels in cells expressing another isoform of CPT1 family member CPT1C, which was identified as a potential LSTase from Swiss-Prot search in addition to CPT1A ([Figure S1A](#SD6){ref-type="supplementary-material"}). We ectopically expressed CPT1C in 293T cells and measured the total lysine succinylation levels in lysates by WB with a pan anti-succinylated lysine antibody. Expression of CPT1C WT did not increase the total lysine succinylation levels in 293T cell lysates compared with expression of vector control ([Figure S1D](#SD6){ref-type="supplementary-material"}).

Identification of CPT1A-Dependent Lysine-Succinylated Proteins Using a SILAC-Based Quantitative Proteomics Approach {#S5}
-------------------------------------------------------------------------------------------------------------------

To identify CPT1A-dependent lysine-succinylated proteins and the sites of succinylation, we next performed quantitative succinylation analysis using stable isotope labeling by amino acid in cell culture (SILAC). 293T cells stably transfected with vector control (vector control cells) were incubated with light (L) \[U-12C6\]-lysine, while 293T CPT1A WT cells were incubated with heavy (H) \[U-13C6\]-lysine. Lysates from these two cell lines were mixed in a 1:1 ratio. One half of the mixed lysates was used for quantitative liquid chromatography (LC)-MS analysis for the total peptide normalization, and the other half was used for affinity enrichment by immunoprecipitation with pan anti-succinylated lysine antibody-conjugated beads followed by LC-MS/MS ([Figure 1B](#F1){ref-type="fig"}). We found that succinylation levels of 171 unique lysine sites on 101 proteins (31% of the total 550 detected unique lysine sites on 247 proteins) were increased by more than 1.5-fold in CPT1A WT cells compared with vector control cells ([Figure 1C](#F1){ref-type="fig"}; [Tables S1](#SD2){ref-type="supplementary-material"} and [S2](#SD3){ref-type="supplementary-material"}). These results suggest that CPT1A regulates lysine succinylation in cells. We also investigated the possibility that the increased succinylation bands could be degradation products of expressed CPT1A ([Figure 1A](#F1){ref-type="fig"}). We found no lysine-succinylated CPT1A peptide in our SILAC proteomics data from the CPT1A-expressed 293T cell lysates ([Table S1](#SD2){ref-type="supplementary-material"}), indicating that the increased succinylation bands by CPT1A expression would appear to be the lysine-succinylated downstream substrate proteins.

Using the SILAC proteomics data, we next examined the sub-cellular distribution of the CPT1A-dependent lysine-succinylated proteins and assessed whether there is a consensus sequence motif for CPT1A-dependent lysine succinylation. We found that almost 50% of the proteins with greater than a 1.5-fold increase in succinylation were cytosolic proteins ([Figure 1D](#F1){ref-type="fig"}; [Table S2](#SD3){ref-type="supplementary-material"}). Analysis of the amino acids flanking the 171 succinylated lysines revealed that they were enriched in nonpolar hydrophobic amino acids such as leucine, valine, and isoleucine ([Figure 1E](#F1){ref-type="fig"}; [Table S2](#SD3){ref-type="supplementary-material"}). These results are in contrast to recent studies on SIRT5 showing that most of the SIRT5-dependent lysine-succinylated proteins were mitochondrial proteins and that succinylated lysine sites targeted by SIRT5 tended to be near glycine, alanine, serine, or threonine residues ([@R16]; [@R19]). These differences may be because the substrate binding sites of CPT1A are exposed to the cytosolic side of the mitochondrial outer membrane, while SIRT5 localizes to the mitochondrial matrix. Supporting this reasoning, among 32 mitochondrial CPT1A-dependent lysine-succinylated proteins (32% of the total 101 CPT1A-dependent lysine-succinylated proteins), only 8 proteins were previously identified as potential SIRT5 substrates ([Figure 1D](#F1){ref-type="fig"}; [Table S2](#SD3){ref-type="supplementary-material"}) ([@R16]).

CPT1A Is a Regulator of Lysine Succinylation In Vivo and Can Lysine-Succinylate Enolase 1 to Inhibit Enolase 1 Activity In Vitro {#S6}
--------------------------------------------------------------------------------------------------------------------------------

To further examine the role of CPT1A as an LSTase in cells, we knocked down endogenous CPT1A by short hairpin RNA (shRNA) in a breast cancer cell line, T47D cells, which express high levels of CPT1A. We found that CPT1A knockdown (KD) decreased total lysine succinylation levels in lysates ([Figure 2A](#F2){ref-type="fig"}). We further performed SILAC succinyl proteomics analysis using T47D cells with or without stable KD of CPT1A, as similarly performed in 293T cells ([Figure 1B](#F1){ref-type="fig"}). In this case, T47D cells stably transfected with vector control (vector control cells) were incubated with L \[U-12C6\]-lysine, while T47D cells stably expressing shRNA against CPT1A (CPT1A KD cells) were incubated with H \[U-13C6\]-lysine. The SILAC succinyl proteomics data showed that succinylation levels of 156 unique lysine sites were decreased by more than 1.3-fold in CPT1A KD cells compared with vector control cells (13% of the total 1,202 detected unique succinyl lysine sites) ([Figure 2B](#F2){ref-type="fig"}; [Table S3](#SD4){ref-type="supplementary-material"}), suggesting that CPT1A KD caused the overall decrease in lysine succinylation in T47D cells. Furthermore, to verify CPT1A-dependent lysine succinylation in cells, we developed an anti-succinylated lysine motif antibody using a peptide library containing the succinylated motif sequence LVxx(succ)K that we identified using SILAC ([Figure 1E](#F1){ref-type="fig"}). The specificity of this antibody was confirmed by dot blot assay, which showed that the antibody did not recognize acetyl, malonyl, glutaryl lysines, or other acyllysine modifications ([Figure 2C](#F2){ref-type="fig"}). Similar to our findings in [Figure 1A](#F1){ref-type="fig"}, WB with the anti-LVxx(succ)K antibody showed that CPT1A WT expression increased LVxxK succinylation in 293T cells ([Figure 2D](#F2){ref-type="fig"}). Together, these results support the notion that CPT1A is a regulator of lysine succinylation *in vivo*.

We next sought to examine the effects of CPT1A as an LSTase on individual substrate proteins. We focused on enolase 1 because it contained the greatest number of succinylation sites of the 40 proteins identified in our SILAC analysis using CPT1A-expressed 293T cells ([Figures S2A and S2B](#SD6){ref-type="supplementary-material"}). We ectopically expressed Flag-tagged enolase 1 in 293T cells and showed that CPT1A WT expression increased LVxxK succinylation of immunoprecipitated Flag-tagged enolase 1 compared with expression of the vector control ([Figure 3A](#F3){ref-type="fig"}), confirming our SILAC proteomics data. We further performed WB analysis of two more identified potential CPT1A substrate proteins (creatine kinase B \[CKB\] and 14-3-3 zeta), one non-target protein that was not detected by our SILAC analysis (glutathione S-transferase \[GST\]), and one identified protein in which lysine succinylation was decreased by CPT1A expression (histone 4 \[H4\]). We separately expressed Flag-tagged CKB, GST-tagged 14-3-3 zeta, and GST alone in 293T cells and showed that CPT1A WT expression increased LVxxK succinylation of immunoprecipitated Flag-tagged CKB and pulled down GST-tagged 14-3-3 zeta compared with vector control, but no LVxxK succinylation was observed in pulled-down GST protein alone from 293T cells expressing CPT1A ([Figures S3A--S3C](#SD6){ref-type="supplementary-material"}). We also showed that CPT1A WT expression decreased K32 succinylation of H4 in 293T cells, but the mechanism of the reduction in H4 K32 succinylation by CPT1A expression remains elusive ([Figure S3D](#SD6){ref-type="supplementary-material"}). These results together validate the accuracy of our SILAC succinyl proteomics data.

To examine whether CPT1A directly succinylates lysine residues *in vitro*, we purified recombinant CPT1A WT as well as CPT1A H473A, a catalytically inactive mutant that disrupts the putative binding pocket for the sulfur atom of the acyl-CoA thioester ([@R11]; [@R14], [@R15]) ([Figure S3E](#SD6){ref-type="supplementary-material"}). Next, to evaluate the structural properties of purified CPT1A WT and H473A proteins, we examined the relative stability of the CPT1A proteins to limited proteolytic digestion by trypsin as described previously ([@R8]). Silver staining results showed that there was no obvious difference in the digestion patterns of trypsin-treated CPT1A WT and H473A mutant proteins, suggesting that H473A mutation does not disrupt the overall structure of CPT1A protein ([Figure S3F](#SD6){ref-type="supplementary-material"}). It is of note that purified CPT1A WT protein, but not purified CPT1A H473A proteins, still possesses the canonical CPTase activity *in vitro* ([Figure S3G](#SD6){ref-type="supplementary-material"}). We next incubated the purified CPT1A proteins with purified enolase 1 in the presence of 50 μM succinyl-CoA, which is below the physiological concentration of succinyl-CoA in 293T cells (100 μM) ([Figure S1B](#SD6){ref-type="supplementary-material"}). WB analysis showed that CPT1A WT, but not CPT1A H473A, succinylated enolase 1 on lysines, thus demonstrating that purified CPT1A can directly succinylate enolase 1 *in vitro* and that the H473A mutant lacks LSTase activity ([Figure 3B](#F3){ref-type="fig"}, left). To assess whether lysine succinylation affects enolase 1 catalytic activity, we incubated purified enolase 1 with CPT1A WT and CPT1A H473A and assayed enolase activity. CPT1A WT significantly inhibited enolase 1, whereas CPT1A H473A did not ([Figure 3B](#F3){ref-type="fig"}, right). Together, these results suggest that enolase 1 is a substrate for CPT1A and lysine succinylation of enolase 1 by CPT1A alters enolase 1 catalytic activity. We further performed the *in vitro* succinyltransferase assay to show (1) that BSA, which is a protein that is not a target of CPT1A, is not succinylated ([Figure 3C](#F3){ref-type="fig"}); (2) a time-dependent increase in succinylation on enolase 1 by CPT1A ([Figure 3D](#F3){ref-type="fig"}); and (3) a dose-dependent increase in succinylation on enolase 1 by increased amount of CPT1A ([Figure 3E](#F3){ref-type="fig"}). In addition, we did not observe the time-dependent increase in lysine succinylation of enolase 1 without CPT1A or without succinyl-CoA ([Figure S3H](#SD6){ref-type="supplementary-material"}) and demonstrated that no lysine succinylation on enolase 1 was induced by CPT1A with malonyl-CoA ([Figure S3I](#SD6){ref-type="supplementary-material"}).

To further investigate which succinylated lysine sites are responsible for enolase 1 inhibition by CPT1A, we first separately introduced succinylation mimic K-to-E mutations into enolase 1. These mutations included major succinylated lysine sites such as K5, K80, K89, and K233 identified from our SILAC succinyl proteomics data. Although K81 has lowest stoichiometry of succinylation within enolase 1, we introduced K80/81E mutations together because of the proximity of the two sites ([Figure S3J](#SD6){ref-type="supplementary-material"}). We also introduced another K335E mutation because K335 is proximal to the substrate binding region of enolase 1 ([@R9]). We assayed enolase activity of WT, K5 K80/81E, K89E, K233E, and K335E proteins and found that K80/81E and K335E mutant exhibited lower enzymatic activity compared with WT, suggesting that K80/81 and K335 succinylation are likely important for the inhibition of enolase 1 by lysine succinylation ([Figure S3K](#SD6){ref-type="supplementary-material"}). On the basis of these results, we further made succinylation deficient 3KR mutant protein in which all the K80/81 and K335 sites were substituted to Arg (R) and incubated with purified CPT1A WT along with succinyl-CoA and assayed for enolase activity. Purified CPT1A WT did not inhibit the 3KR mutant protein, suggesting that succinylation on K80/81 and K335 is important for CPT1A-dependent inhibition of enolase 1 ([Figure 3F](#F3){ref-type="fig"}). It is of note that the protein sequence surrounding K80/81 of enolase 1 is IAPA(LVSKK)LNVTEQ, which contains the LVxxK motif sequence. In addition, we performed the *in vitro* succinyltransferase assay using purified CPT1A WT and enolase 3KR mutant followed by WB analysis with anti-pan succinyl lysine, anti-CPT1A, and anti-enolase 1 antibodies. The WB results showed that CPT1A did not increase lysine succinylation on enolase 3KR mutant, suggesting that any or all of K80, K81, and K335 are major succinylation sites by CPT1A in the *in vitro* succinyltransferase assay ([Figure S3L](#SD6){ref-type="supplementary-material"}). Consistent with this finding, we observed that CPT1A KD decreased lysine succinylation of Flag-enolase 1 WT, but not Flag-enolase 1 3KR, compared with vector control in T47D cells ([Figure S3M](#SD6){ref-type="supplementary-material"}). These results support our notion that endogenous CPT1A can regulate lysine succinylation of enolase 1 in cells.

Physiological Significance of CPT1A-Dependent Lysine Succinylation in Cells {#S7}
---------------------------------------------------------------------------

Because CPT1A H473A lacks both LSTase and CPTase activities ([Figures 3B](#F3){ref-type="fig"} and [S3G](#SD6){ref-type="supplementary-material"}), we sought a CPT1A mutation that separates LSTase and CPTase activities so that we could assess the impact of selectively disabling the LSTase activity in cells. We found that expression of the previously reported CPTase-deficient mutant CPT1A G710E ([@R18]) increased total LVxxK succinylation levels to a similar extent as expression of CPT1A WT in lysates of 293T cells ([Figure 4A](#F4){ref-type="fig"}). We also confirmed that expression of CPT1A WT, but not G710E mutant, increased the CPTase activity in 293T cells compared with expression of vector control although G710E mutant lysine succinylates enolase 1 to a similar extent as CPT1A WT in the *in vitro* succinyltransferase assay ([Figures 4B](#F4){ref-type="fig"} and [S3I](#SD6){ref-type="supplementary-material"}). G710E mutation was identified from patients with CPT1A deficiency and is a natural mutation that decreases the activity without changing the protein stability ([@R18]). Because no crystal structure of CPT1A has been reported yet, a previous study of structure modeling of CPT1A used the crystal structure of mouse carnitine acetyltransferase and showed that G710 is proximal to the catalytic H473 site, and the introduction of a negative charge may impair the catalytic process of the classical CPTase activity of CPT1A by inhibiting the binding of palmitoyl group to the putative substrate binding pocket ([@R15]).

We also measured FAO activity in 293T cell lines expressing CPT1A WT and mutants as well as vector control by monitoring the conversion rate of \[U-13C\]-palmitate to \[2-13C\]-citrate. We unexpectedly observed no significant alteration of FAO activity by expression of CPT1A WT compared with expression of vector control and CPT1A mutants in 293T cells ([Figure 4C](#F4){ref-type="fig"}). These results may be explained by our finding from the global proteomics data that stable expression of CPT1A WT in 293T cells decreased expression levels of enzymes related to FAO pathway such as very long-chain specific acyl-CoA dehydrogenase (ACADVL), acyl-CoA dehydrogenase family member (ACAD) 9 and 11, 3-ketoacyl-CoA thiolase (ACAA), and 3-hydroxyacyl-CoA dehydrogenase type-2 (HSD17B10), which might decrease the activity of FAO to cancel out the effect of CPT1A WT expression while the mechanism underlying the decrease in expression levels of these proteins remains elusive ([Figure S4A](#SD6){ref-type="supplementary-material"}; [Table S1](#SD2){ref-type="supplementary-material"}).

To further ask whether the classical CPTase activity of endogenous CPT1A affects its LSTase activity, we treated breast cancer BT474 cells expressing high levels of endogenous CPT1A with an irreversible inhibitor of CPT1, etomoxir. We found that overnight etomoxir treatment reduced FAO activity to less than 10% but did not affect total LVxxK succinylation levels ([Figure S4B](#SD6){ref-type="supplementary-material"}). Because KD of CPT1A decreased total succinylation in BT474 cell lysates ([Figure 4K](#F4){ref-type="fig"}), these data together suggest that the CPTase activity and LSTase activity are independently regulated by CPT1A.

The results from [Figures 4A and 4B](#F4){ref-type="fig"} led us to use CPT1A G710E mutant for the following enolase activity assay in cell lysates as well as cell proliferation assay to examine the physiological functions of CPT1A-dependent lysine succinylation in cells. A previous proteomics study showed that among enolase isoforms, only enolase 1-derived peptides were detected in hematopoietic Ba/F3 cells ([@R17]), suggesting that enolase 1 is predominantly expressed in Ba/F3 cells, and the total enolase activity in Ba/F3 cell lysates represents the activity of enolase 1. We therefore generated Ba/F3 cells stably expressing vector control, CPT1A WT, CPT1A H473A, and CPT1A G710E and examined the total enolase activity in lysates. Consistent with the results from [Figures 3B](#F3){ref-type="fig"} and [4A](#F4){ref-type="fig"}, expression of CPT1A WT and CPT1A G710E, but not CPT1A H473A, increased total LVxxK succinylation and inhibited enolase enzyme activity in lysates without altering enolase 1 protein levels compared with vector control ([Figures 4D and 4E](#F4){ref-type="fig"}). Furthermore, consistent with the results from [Figures S1B and 4C](#SD6){ref-type="supplementary-material"}, we did not observe any significant alteration in intracellular succinyl-CoA levels or FAO activity between these Ba/F3 cell lines ([Figures 4F and 4G](#F4){ref-type="fig"}). Taken together, these results suggest that the LSTase activity, but not the CPTase activity, of CPT1A inhibits enolase in cells.

A recent study showed that shRNA-based silencing of enolase 1 expression induces senescence in breast cancer MDA-MB 231 cells but promotes cell survival under conditions in which glutamine metabolism is suppressed by the glutaminase inhibitor BPTES (bis-2-\[5phenylacetamido-1,2,4- thia-diazol-2-yl\] ethyl sulfide) ([@R1]). This led us to test whether the LSTase activity of CPT1A that inhibits enolase 1 may contribute to cell proliferation in glutamine-free medium. We found that CPT1A WT and G710E mutant-expressing Ba/F3 cells, but not H473A mutant-expressing Ba/F3 cells, exhibited increased cell proliferation in glutamine-free medium compared with vector control cells ([Figure 4H](#F4){ref-type="fig"}). There was no significant difference in proliferation of these stable cell lines in complete medium ([Figure S4C](#SD6){ref-type="supplementary-material"}). Consistent with these results, CPT1A WT and G710E-expressed 293T cells exhibited increased cell proliferation in glutamine-free medium compared with vector control cells ([Figure S4D](#SD6){ref-type="supplementary-material"}). These results suggest that the LSTase activity, but not the CPTase activity, of CPT1A promotes cell proliferation under glutamine depletion.

To further examine whether the increase in glutamine-independent Ba/F3 cell proliferation by CPT1A WT and by G710E mutant is mediated through enolase inhibition, we treated Ba/F3 cells with an enolase-specific inhibitor, ENOblock, to mimic the inhibition effect of CPT1A on enolase 1 ([@R7]). We found that 0.5 μM ENOblock treatment reduced enolase 1 activity to a similar extent as in the lysates from CPT1A WT or G710E mutant-expressed Ba/F cells (50% decrease from control treatment or control vector cells) ([Figures 4E and 4I](#F4){ref-type="fig"}). Consistent with our findings, 0.5 μM ENOblock treatment significantly increased cell proliferation in glutamine-free medium but not in complete medium compared with vehicle treatment ([Figures 4J](#F4){ref-type="fig"} and [S4E](#SD6){ref-type="supplementary-material"}), suggesting that the LSTase activity of CPT1A promotes glutamine-independent Ba/F3 cell proliferation at least in part through the inhibition of enolase. We also performed cell proliferation assay of the CPT1A-expressed Ba/F3 cell lines treated with etomoxir in glutamine-free medium and found that expression of CPT1A WT and G710E, but not H73A, increased Ba/F3 cell proliferation compared with vector control even in the presence of etomoxir in glutamine-free medium ([Figure S4F](#SD6){ref-type="supplementary-material"}), suggesting that the growth enhancement observed in glutamine-free medium with expression of CPT1A was not due to the alteration of FAO. We also found no significant alteration in cell proliferation among these Ba/F3 cell lines when treated with AICAR as well as ENOblock and 2-DG in complete medium ([Figures S4G and S4H](#SD6){ref-type="supplementary-material"}).

To further study the physiological relevance of the LSTase activity of endogenous CPT1A, we sought to examine CPT1A KD BT474 cells of which lysine succinylation levels were decreased in lysates compared with vector control cells ([Figure 4K](#F4){ref-type="fig"}). We confirmed that CPT1A KD did not cause any changes in enolase 1 expression levels and succinyl-CoA levels in BT474 cells ([Figures 4K and 4L](#F4){ref-type="fig"}). It is difficult to assess enolase activity in lysates from BT474 cells with high expression of endogenous SIRT5 compared with other SIRT family members ([Table S4](#SD5){ref-type="supplementary-material"}), which may desuccinylate enolase to change its activity during cell lysis. To solve this problem, we incubated BT474 cells with \[U-13C6\]-glucose and measured the conversion rate of \[3-13C\]-2PG (enolase substrate) to \[3-13C\]-PEP (enolase product), which represents enolase activity in cells. We found that CPT1A KD cells displayed significantly higher conversion rate of \[3-13C\]-2PG to \[3-13C\]-PEP than vector control cells, suggesting that CPT1A KD increased enolase activity in BT474 cells ([Figure 4M](#F4){ref-type="fig"}). To examine whether the observed increase in the total enolase activity by CPT1A KD in BT474 cells is due to changes in enolase 1, we performed total proteomics analysis of BT474 cell lysates. We found that signal intensities from enolase 1-derived peptides were 200 times higher than those from enolase 2-derived peptides, and no other enolase isoforms were detected ([Table S4](#SD5){ref-type="supplementary-material"}). These results suggest that enolase 1 is predominantly expressed in BT474 cells and the increase in enolase activity by CPT1A KD in BT474 cells is likely due to changes in enolase 1.

Finally, we performed proliferation assays of vector control and CPT1A KD BT474 cells and demonstrated that CPT1A KD significantly decreased cell proliferation in glutamine-free medium but not in complete medium ([Figures 4N and 4O](#F4){ref-type="fig"}). All of the data in [Figures 4K--4O](#F4){ref-type="fig"} are consistent with the other data in [Figure 4](#F4){ref-type="fig"} and support the notion that the CPT1A increases total lysine succinylation levels without affecting intracellular succinyl-CoA levels to inhibit enolase 1 and enhances glutamine-independent cell proliferation.

Altogether we showed that CPT1A lysine succinylated its substrate proteins *in vivo* and *in vitro*, and such LSTase activity inhibits enolase 1 and promotes cell proliferation under glutamine depletion independent of its classical CPTase activity. These data provide evidence not only for the role of CPT1A as an LSTase but also a functional effect of CPT1A-dependent lysine succinylation on a substrate protein and cellular metabolism. Furthermore, we identified 101 potential CPT1A substrate proteins, expanding the understanding of lysine succinylation-dependent signal transduction in cells. However, it remains unclear how lysine succinylation affects the inhibition of CPT1A by malonyl-CoA, and it also is possible that any alteration in the succinyl-CoA level can regulate the levels of succinylation besides the LSTase activity of CPT1A. Hence, further work would be needed to resolve these issues.

EXPERIMENTAL PROCEDURES {#S8}
=======================

Statistical Methods {#S9}
-------------------

Significance was tested using unpaired two-tailed Student's t tests, assuming independent variables, normal distribution, and equal variance of samples. Data are presented as mean ± SD from three independent measurements. A p value \< 0.05 was considered to indicate statistical significance.

In Vitro Succinyltransferase Assay {#S10}
----------------------------------

Purified recombinant CPT1A proteins (100 ng) were incubated with purified recombinant enolase 1 protein (100 ng) at 30°C for 2 hr in 50 μL of the buffer containing 10 mM HEPES (pH 7.5), 2 mM sodium orthovanadate, 5 mM sodium pyrophosphate, 300 mM NaCl, and 1% Nonidet P-40 plus 50 μM succinyl-CoA as a substrate and 50 ng of BSA as a protein stabilizer. The reaction was terminated by the addition of 6xSDS sample buffer and by boiling the samples for 5 min.

CPTase Activity Assay {#S11}
---------------------

CPTase activity was measured using 10 μCi L-\[^3^H\]carnitine as previously described ([@R4]).

Metabolic Flux Analysis of FAO {#S12}
------------------------------

FAO activity was measured by monitoring the conversion rate of \[U-13C\]-palmitate to \[2-13C\]-citrate with GC/MS. In brief, the cells were incubated with 100 μM \[U-13C\]-palmitate-BSA conjugate for overnight. After the incubation, the metabolites were extracted and dried up and then derivatized with MSTFA. The FAO activity was calculated by dividing the citrate labeling rate by the palmitate uptake rate.

Cell Proliferation Assay {#S13}
------------------------

Fold increase in cell proliferation was determined by measuring the cell viability at the indicated days divided by the starting cell viability at day 1 using the CyQUANT Cell Proliferation Assay Kit (Thermo Fisher Scientific).
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![Identification of CPT1A-Dependent Lysine-Succinylated Proteins Using a SILAC-Based Quantitative Proteomics Approach\
(A) Left: WB of lysates from 293T cells stably expressing vector control and CPT1A WT with anti-pan-succinylated lysine, anti-CPT1A, and anti-β-actin antibodies. Right: GC-MS analysis of succinyl-CoA extracted from 293T cells expressing vector control and CPT1A WT. Error bars, ±SD of three independent measurements. P values were determined using a two-tailed Student's t test. n.s., not significant.\
(B) Schematic diagram of the SILAC-based quantitative proteomics approach for the identification of CPT1A-dependent lysine succinylation.\
(C) Summary of the quantified lysine-succinylated sites and proteins.\
(D) Subcellular distribution of CPT1A-dependent lysine-succinylated proteins.\
(E) Consensus sequence motif logo for the amino acid sequences surrounding the 171 CPT1A-dependent succinylated lysine sites (\>1.5-fold).\
See also [Figure S1](#SD6){ref-type="supplementary-material"} and [Tables S1](#SD2){ref-type="supplementary-material"} and [S2](#SD3){ref-type="supplementary-material"}.](nihms943494f1){#F1}

![CPT1A Is a Major Regulator of Lysine Succinylation *In Vivo*\
(A) WB of lysates from T47D cells stably expressing vector control and CPT1A shRNA with anti-succinylated lysine, anti-CPT1A, and anti-β-actin antibodies.\
(B) Summary of the quantified lysine-succinylated sites in T47D cells with CPT1A KD from SILAC analysis.\
(C) Left: dot blotting of unmodified and acylated lysine peptides including succinylated lysine motif LVxx(succ)K, acetyllysine (ace)K, propionyllysine (prop)K, butyryllysine (bu)K, 2-methyllysine (me2)K, 2-hydroxyisobutyryllysine (2ohibu)K, and crotonyllysine (cro)K peptides with anti-LVxx(succ)K antibody. Right: dot blotting of unmodified and succinylated lysine LVxx(succ)K, malonylated lysine LVxx(mal)K, (mal)K, and glutarylated lysine LVxx(glu)K, (glu)K peptides with anti-LVxx(succ)K antibody.\
(D) WB of lysates from 293T cells stably expressing vector control and CPT1A WT with anti-LVxx(succ) K succinylated lysine motif, anti-CPT1A, and anti-β-actin antibodies.\
See also [Figure S2](#SD6){ref-type="supplementary-material"} and [Table S3](#SD4){ref-type="supplementary-material"}.](nihms943494f2){#F2}

![CPT1A Lysine Succinylates Enolase 1 to Inhibit Its Enzymatic Activity\
(A) Immunoprecipitated Flag-tagged enolase 1 was western blotted with anti-LVxx(succ)K succinylated lysine motif and anti-Flag antibodies. Lysates were western blotted for CPT1A and β-actin.\
(B) Left: WB of the *in vitro* succinyltransferase assay samples using purified CPT1A WT or H473A and enolase 1 with anti-pan-succinylated lysine, anti-CPT1A, and anti-enolase 1 antibodies. Right: enolase activity of the *in vitro* succinyltransferase assay samples.\
(C) WB of the *in vitro* succinyltransferase assay samples using purified CPT1A WT and BSA with anti-pan-succinylated lysine, anti-CPT1A, and anti-BSA antibodies.\
(D) WB of the *in vitro* succinyltransferase assay samples at the indicated time points with anti-pan-succinylated lysine, anti-CPT1A, and anti-enolase 1 antibodies.\
(E) WB of the *in vitro* succinyltransferase assay using the indicated amounts of purified CPT1A WT and enolase 1 with anti-pan-succinylated lysine, anti-CPT1A, and anti-enolase 1 antibodies.\
(F) Enolase activity of the *in vitro* succinyltransferase assay samples using purified CPT1A WT with enolase 1 WT or 3KR.\
Error bars, ±SD of three independent measurements. P values were determined using a two-tailed Student's t test. \*\*p \< 0.01; n.s., not significant. See also [Figure S3](#SD6){ref-type="supplementary-material"}.](nihms943494f3){#F3}

![LSTase Activity of CPT1A Promotes Hematopoietic Cell Proliferation Under Glutamine Depletion\
(A) Lysates from 293T cells stably expressing vector control, CPT1A WT, and CPT1A G710E were western blotted with anti-LVxx(succ)K, anti-CPT1A, and anti-β-actin antibodies.\
(B) CPTase activity of membrane proteins from 293T cells stably expressing vector control, CPT1A WT and G710E.\
(C) FAO activity in 293T cells expressing vector control, CPT1A WT, and G710E.\
(D) WB of lysates from Ba/F3 cells stably expressing vector control, CPT1A WT, H473A, and G710E with anti-LVxx(succ)K, anti-CPT1A, anti-enolase 1, and anti-β-actin antibodies.\
(E) Enolase activity of lysates from Ba/F3 cells stably expressing vector control, CPT1A WT, H473A, and G710E.\
(F) GC/MS analysis of succinyl-CoA extracted from Ba/F3 cells expressing vector control, CPT1A WT, H473A, and G710E.\
(G) FAO activity in Ba/F3 cells expressing vector control, CPT1A WT, H473A, and G710E.\
(H) Glutamine-independent proliferation of Ba/F3 cells stably expressing vector control, CPT1A WT, H473A, and G710E.\
(I) Enolase activity of lysates from Ba/F3 cells treated with vehicle control and 0.5 μM ENOblock.\
(J) Glutamine-independent proliferation of Ba/F3 cells treated with vehicle control and 0.5 μM ENOblock.\
(K) WB of lysates from BT474 cells stably expressing vector control and CPT1A shRNA with anti-succinylated lysine, anti-CPT1A, anti-enolase 1, and anti-β-actin antibodies.\
(L) GC/MS analysis of succinyl-CoA extracted from BT474 cells stably expressing vector control and CPT1A shRNA.\
(M) GC/MS analysis of enolase activity by measuring the conversion rate of \[3-13C\]-2PG to \[3-13C\]-PEP in cells incubated with \[U-13C6\]-glucose.\
(N) Proliferation of BT474 cells expressing vector control and CPT1A shRNA in complete medium.\
(O) Proliferation of BT474 cells expressing vector control and CPT1A shRNA in glutamine-free medium.\
Error bars, ±SD of three independent measurements. P values were determined by a two-tailed Student's t test. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001; n.s., not significant. See also [Figure S4](#SD6){ref-type="supplementary-material"} and [Table S4](#SD5){ref-type="supplementary-material"}.](nihms943494f4){#F4}

###### Highlights

-   CPT1A succinylates proteins in vitro using succinyl-CoA as a substrate

-   CPT1A increases lysine succinylation in cells without altering succinyl-CoA levels

-   CPT1A inhibits enolase 1 by lysine succinylation in vivo and in vitro

-   About 100 CPT1A-dependent succinylated proteins were identified

[^1]: Present address: Duke Clinical Research Institute, Durham, NC 27705, USA

[^2]: Lead Contact
